At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
Omadacyclinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Multi-Center Study to Measure the Pharmacokinetics of Oral Omadacycline in Adult Subjects With Community-Acquired Bacterial Pneumonia (CABP)
In Brief
A Phase 1 clinical trial evaluating Omadacycline for Community-acquired Pneumonia. Completed, enrolled 18 participants across 13 sites.
Detailed Summary
The purpose of this study is to evaluate the pharmacokinetics of an oral omadacycline dosing regimen in the treatment of adults with CABP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommunity-acquired Pneumonia
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartNov 2019
Primary CompletionMar 2020
Study CompletionApr 2020
TodayJul 2026
First PostedNov 12, 2019
Enrollment StartNov 28, 2019
Primary CompletionMar 23, 2020
Study CompletionApr 13, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.6 years ago
Interventions
Omadacyclinedrug
Omadacycline: PO Tablets